Liso-cel, a CART product that features a consistent 1:1 CD4 + :CD8 + CART ratio, was evaluated in the larger phase 1/2 TRANSCEND CLL 004 trial, which was the basis for the recent U.S. Food and Drug Administration approval of liso-cel for the treatment of adults with r/r CLL or small lymphocytic lymphoma. The gene discussed is CD8A; the disease is B-cell chronic lymphocytic leukemia.